Details

Autor(en) / Beteiligte

• Ahmed, Ahmed T.
• MahmoudianDehkordi, Siamak
• Bhattacharyya, Sudeepa
• Arnold, Matthias
• Liu, Duan
• Neavin, Drew
• Moseley, M. Arthur
• Thompson, J. Will
• Williams, Lisa St John
• Louie, Gregory
• Skime, Michelle K.
• Wang, Liewei
• Riva-Posse, Patricio
• McDonald, William M.
• Bobo, William V.
• Craighead, W. Edward
• Krishnan, Ranga
• Weinshilboum, Richard M.
• Dunlop, Boadie W.
• Millington, David S.
• Rush, A. John
• Frye, Mark A.
• Kaddurah-Daouk, Rima

Titel

Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes

Ist Teil von

• Journal of affective disorders, 2020-03, Vol.264, p.90-97

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •This study was to assess whether three symptomatically defined phenotypes of MDD, (core depression, neurovegetative of melancholia and anxiety), could be differentiated based on acylcarnitine profiles at baseline, after eight weeks of citalopram/escitalopram treatment.•The current data demonstrated that these phenotypes have distinct patterns of acylcarnitine levels at baseline and after eight weeks of antidepressant treatment.•These findings may help to develop a metabolomic profile of MDD patients with the aim of improving subtype classification of the MDD syndrome. Acylcarnitines have important functions in mitochondrial energetics and β-oxidation, and have been implicated to play a significant role in metabolic functions of the brain. This retrospective study examined whether plasma acylcarnitine profiles can help biochemically distinguish the three phenotypic subtypes of major depressive disorder (MDD): core depression (CD+), anxious depression (ANX+), and neurovegetative symptoms of melancholia (NVSM+). Depressed outpatients (n = 240) from the Mayo Clinic Pharmacogenomics Research Network were treated with citalopram or escitalopram for eight weeks. Plasma samples collected at baseline and after eight weeks of treatment with citalopram or escitalopram were profiled for short-, medium- and long-chain acylcarnitine levels using AbsoluteIDQ®p180-Kit and LC-MS. Linear mixed effects models were used to examine whether acylcarnitine levels discriminated the clinical phenotypes at baseline or eight weeks post-treatment, and whether temporal changes in acylcarnitine profiles differed between groups. Compared to ANX+, CD+ and NVSM+ had significantly lower concentrations of short- and long-chain acylcarnitines at both baseline and week 8. In NVSM+, the medium- and long-chain acylcarnitines were also significantly lower in NVSM+ compared to ANX+. Short-chain acylcarnitine levels increased significantly from baseline to week 8 in CD+ and ANX+, whereas medium- and long-chain acylcarnitines significantly decreased in CD+ and NVSM+. In depressed patients treated with SSRIs, β-oxidation and mitochondrial energetics as evaluated by levels and changes in acylcarnitines may provide the biochemical basis of the clinical heterogeneity of MDD, especially when combined with clinical characteristics.